Results 91 to 100 of about 127,436 (249)

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han   +45 more
wiley   +1 more source

Factor VIII Activity in Relation to the Type of Thrombosis and Patient’s Risk Factors for Thrombosis, Age, and Comorbidity

open access: yesEurasian Journal of Medicine, 2023
Dusica Basaric   +5 more
doaj   +1 more source

Transfusion biomaterials for hemostasis

open access: yesJournal of Thrombosis and Haemostasis
Bleeding is a leading cause of trauma deaths and surgical complications. Excessive bleeding has traditionally been treated with the transfusion of donated blood. However, the complicated logistics of sourcing and storing donated blood increases the cost and reduces the accessibility of treatment, particularly as rates of blood donation decline ...
Ethan Pozy, Ashley C. Brown
openaire   +3 more sources

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano   +52 more
wiley   +1 more source

Thrombin cleaves membrane-bound endoglin potentially contributing to the heterogeneity of circulating endoglin in preeclampsia

open access: yesCommunications Biology
Increased levels of soluble endoglin (sEng) are found in serum, plasma, and urine of preeclampsia patients. sEng is released from membrane-bound endoglin through the proteolytic activity of metalloproteases, but its structural heterogeneity suggests the ...
Divina El Hamaoui   +14 more
doaj   +1 more source

MEK inhibitor PD0325901 upregulates CD34 expression in endothelial cells via inhibition of ERK phosphorylation

open access: yesRegenerative Therapy
Introduction: CD34-positive endothelial progenitor cells (EPCs) promote angiogenesis and are a promising tool for regenerative cell therapy of ischemic diseases.
Chihiro Hosoda   +7 more
doaj   +1 more source

Cell‐free DNA for detection and monitoring of extramedullary AML relapse

open access: yesHemaSphere
Isolated extramedullary manifestations (IEM) of acute myeloid leukemia (AML) are recurrent events, especially following allogeneic hematopoietic cell transplantation (alloHCT).
Henri C. Hupe   +19 more
doaj   +1 more source

Hemostasis

open access: yes, 2018
The goal of this thesis is to explore some of the essential ‘factors that matter’ in hemostasis. Adequate hemostasis transforms liquid blood to a solid clot to prevent blood loss when vessel injury occurs. It requires the combined and regulated activity of endothelial, platelet and coagulation factors.
openaire   +2 more sources

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy